Recordati Rare Diseases announced five research presentations and two published abstracts for the upcoming 68th American Society of Hematology (ASH) Annual Meeting, scheduled for December 12-15, 2026, in New Orleans. The data focuses on long-term safety and efficacy of ENJAYMO (sutimlimab) for cold agglutinin disease and introduces a new symptom burden scale for idiopathic multicentric Castleman disease.
Neutral
🤖 60%
Recordati announces five research presentations plus two published abstracts on its rare hematology portfolio at the ASH Annual Meeting on December 12-15, 2026, in New Orleans. This supports the profile of ENJAYMO (sutimlimab) with consensus guidelines, a Phase 3 post-hoc analysis and real-world registry data, but the announcement contains no new revenue, contract or regulatory figures that would change the company's financial outlook.
Catalysts
- • ASH Annual Meeting presentations on CAD and iMCD, December 12-15, 2026
- • Updated global consensus treatment guidelines for cold agglutinin disease
Risk Factors
- • No new pivotal trial results, sales figures or regulatory decisions are included
- • Poster presentations and registry data are exploratory and may not change clinical practice